Related Experiment Video
Updated: Sep 4, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
The Value of the Information That Can Be Generated: Optimizing Study Design to Enable the Study of Treatments
Aaron Dane1, John H Rex2, Paul Newell2
1DaneStat Consulting, Cheshire, United Kingdom.
Abstract:
In traditional phase 3 trials confirming safety and efficacy of new treatments relative to a comparator, a 1-sided type I error rate of 2.5% is traditionally used and typically leads to minimum sizes of 300-600 subjects per study. However, for rare pathogens, it may be necessary to work with data from as few as 50-100 subjects. For areas with a high unmet need, there is a balance between traditional type I error and power and enabling feasible studies. In such cases, an alternative 1-sided alpha level of 5% or 10% should be considered, and we review herein the implications of such approaches. Resolving this question requires engagement of patients, the medical community, regulatory agencies, and trial sponsors.
Insights
For rare diseases, adjusting the statistical significance level (alpha) in clinical trials can enable smaller, feasible studies. This approach balances traditional error rates with the need for timely treatment access.
Area of Science:
- Clinical trial design
- Biostatistics
- Rare disease research
Background:
- Traditional Phase 3 trials use a 1-sided type I error rate of 2.5%, requiring 300-600 subjects.
- Rare pathogen studies may only have 50-100 subjects available.
- High unmet medical needs necessitate balancing statistical rigor with study feasibility.
Purpose of the Study:
- To explore the implications of alternative statistical approaches for clinical trials in rare diseases.
- To evaluate the feasibility of conducting clinical trials with limited subject populations.
- To discuss the balance between type I error rates, statistical power, and sample size in rare disease research.
Main Methods:
- Review of statistical principles for clinical trial design.
- Analysis of the impact of varying alpha levels on study outcomes.
- Examination of the trade-offs between statistical power and sample size.
Main Results:
- Using higher 1-sided alpha levels (5% or 10%) can reduce required sample sizes.
- Alternative alpha levels may impact the balance between detecting efficacy and controlling false positives.
- Feasible studies in rare diseases may necessitate adjusted statistical thresholds.
Conclusions:
- Consideration of higher alpha levels (5% or 10%) is warranted for rare disease trials.
- Stakeholder engagement (patients, medical community, regulators, sponsors) is crucial for adopting new trial designs.
- Balancing statistical rigor with feasibility is key for advancing treatments in areas of high unmet need.
Related Concept Videos
01:20Study Designs in Epidemiology
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
01:15Study Design in Statistics
Does aspirin reduce the risk of heart attacks? Is one brand of fertilizer more effective at growing roses than another? Is fatigue as dangerous to a driver as the influence of alcohol? Questions like these are answered using randomized experiments with proper...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:20Comparing the Survival Analysis of Two or More Groups